Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer’s Disease at the 2015 Alzheimer’s Association International Conference






NEWARK, N.J., July 20, 2015 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) will certainly be showcasing bryostatin as a potential treatment for Alzheimer’s Ailment at the Alzheimer’s Association Worldwide Conference(R) (AAIC) being held July 18-23, 2015, in Washington, DC.

Neurotrope Bioscience has actually an exclusive license to produce and commercialize bryostatin for cognitive disorders.  Bryostatin is a potent modulator of an enzyme called healthy protein kinase C epsilon (PKCε), which has actually been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a feasible treatment of cognitive disorders. Based upon a number of BRNI pre-clinical and autopsy-validated human tissue studies, PKCε deficits have actually been implicated as a potential induce of Alzheimer’s disease. The Company is approaching the treatment of Alzheimer’s Ailment through the activation of PKCε.  In animal models of Alzheimer’s disease, activation of PKCε has actually been shown to boost discovering and memory, improve brain neurotropic factors, and induce synaptogenesis. The Company expects to initiate a Phase 2b trial of bryostatin-1 in roughly 150 patients along with moderately significant to significant Alzheimer’s Ailment later this year.

About the Alzheimer’s Association Worldwide Conference(R) (AAIC)

The Alzheimer’s Association Worldwide Conference(R) (AAIC) is the world’s largest forum for the dementia research community. Worldwide investigators, clinicians and care providers gather annually to share the most recent study results, theories and discoveries to bring the globe closer to breakthroughs in dementia science.

About Alzheimer’s Disease

According to the Alzheimer’s Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer’s disease. Over 500,000 patients are diagnosed annually, along with nearly one-in-eight older Americans affected by the disease. Alzheimer’s Ailment is the third leading induce of death in the United States. There is no cure or efficient treatment for Alzheimer’s disease. Worldwide, Regarding 35.6 million people have actually the Ailment and, according to the globe Healthiness Organization, the number will certainly double every twenty years to 115.4 million people along with Alzheimer’s by 2050.

About Neurotrope

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a concentrate on making a novel therapy for the treatment of moderately significant to significant Alzheimer’s disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can easily result in enhancement of existing synapses, reduces toxic amyloid  generation, promotes synaptogenesis, and improves memory and learning, thus having the potential to boost cognitive function in Alzheimer’s disease. The Company plans to initiate our Phase 2b in 150 moderately significant to significant Alzheimer’s patients in Q4 2015.

Neurotrope is additionally conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Decide on Type C, two rare genetic diseases for which only symptomatic treatments are currently available. We have actually recently been granted Orphan Drug Designation for bryostatin as treatment of Fragile X Syndrome.

NTRP has actually exclusive licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer’s Ailment and Fragile X Syndrome, has actually a world-wide, exclusive license along with the Icahn School of Medicine at Mt. Sinai for Niemann-Decide on Type C and is partnered along with Stanford University to locate the next generation bryostatin – called bryologs.

About The Blanchette Rockefeller Neurosciences Institute

Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer’s patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance along with West Virginia University as well as in collaboration along with various other academic institutions.

Forward-Looking Statements

Any statements contained in this press release, or gained throughout the Company’s presentation at this conference that do not describe historical facts could constitute forward-looking statements. These forward-looking statements contain statements concerning the proposed study and goals, the expectation for timing of results, and continued development of use of bryostatin for Alzheimer’s disease.  Such forward-looking statements are subject to a number of risks and uncertainties and various other influences, several of which the Company has actually no manage over. Actual outcomes and the timing of certain events and circumstances could differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that could influence or induce actual outcomes to differ materially from expected or desired outcomes could include, free of limitation, the Company’s inability to obtain adequate financing, the considerable length of time associated along with drug development and related insufficient money flows and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand the Company’s business, considerable government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition,  stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and various other factors are identified and described in a lot more detail in the Company’s filings along with the SEC, including the Company’s Annual Report on Form 10-Q for the fiscal quarter ended March 31, 2015. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:

Robert Weinstein
Chief Financial Officer
+1-973-242-0005
rweinstein@neurotropebioscience.com

SOURCE Neurotrope, Inc.

RELATED LINKS
http://www.neurotropebioscience.com

Migraine surgery for teens: Good results in initial experience

As in adults, migraine surgery is efficient for decided on adolescent patients along with serious migraine headaches that don’t respond to standard treatments, reports a study in the June issue of Plastic and Reconstructive Surgery®, the official medical diary of the American Society of Plastic Surgeons (ASPS).

ASPS Member Surgeon Bahman Guyuron, MD, Emeritus professor of plastic surgery at Case School of Medicine, Cleveland, and colleagues report good outcomes in an first experience along with migraine surgery in younger patients. They write, “Our data demonstrate that surgery for refractory migraine headaches in the adolescent population could increase and potentially forever ameliorate symptoms for some.”

Young Patients can easily Reward from Migraine Surgery Too

The researchers describe their experience along with migraine surgery in 14 patients under age 18. Dr. Guyuron made the migraine surgery techniques after noticing that some migraine patients had low headache activity after undergoing cosmetic forehead lift procedures going spine to year 2000.

The surgery targets “induce sites” in the nerve branches that make headaches, identified by preoperative evaluation. induce sites are detected using a constellation of symptoms, nerve blocks, ultrasound Doppler and CT scans. Dr. Guyuron and his group have actually published 24 articles in peer-reviewed journals on this topic and efficacy of the surgery, and have actually yet another 12 research projects in process. 5 extra independent centers have actually confirmed Dr. Guyuron’s findings.

All teen patients in the experience had debilitating migraine attacks that continued despite recommended medications. The patients were 11 females and three males, standard age 16 years. One patient underwent two procedures targeting various induce sites. standard follow-up was regarding three years, and at least one year in all of patients.

In this group of young patients, surgery was highly efficient in cutting down migraine headaches. standard headache frequency decreased from 25 per month prior to surgery to 5 per month afterward. standard migraine severity score decreased from 8.2 to 4.3 on a ten-point scale.

The standard time of migraine attacks likewise decreased from regarding 12 hours to 4 hours. 5 of the 14 patients were forever without migraines after surgery. One patient had no modification in migraine frequency, despite the fact that attacks were shorter and much less severe.

Migraine headaches are a common problem in kids and adolescents, and have actually a substantial impact on mental and bodily good health for patients and their families. Treatment selections are limited. One study has actually reported that nearly one-fourth of kids along with neurologist-diagnosed migraine don’t respond to recommended medications. “This represents a large group of adolescent migraine patients along with continued symptoms in spite of specialized medical treatment,” Dr. Guyuron and coauthors write.

Although the experience is small and preliminary, the outcomes suggest that migraine surgery, adore in adults, is safe and efficient in teenaged patients. No complications were encountered in this group of young patients. As in adults, surgery is performed only after careful evaluation in patients that don’t respond to standard migraine treatments, that have actually identifiable induce points and the family history confirms continuation of migraine headaches from childhood to the adult age.

“Recognizing the adolescent patient that would certainly Reward from surgery is the crucial aspect of surgical intervention,” Dr. Guyuron and colleagues write. They emphasize the reason for “much more in-depth and prospective studies” to confirm the effectiveness of migraine surgery, and to weigh the risks and rewards of surgery for younger patients.

Story Source:

The above article is reprinted from materials offered by Wolters Kluwer Health. Note: components could be edited for content and length.

Dermatologist offers unique treatment for vitiligo skin discoloration

A UT Southwestern Medical Focus dermatologist has actually improved a technique to transplant pigment cells that can easily repair the affected area of skin discoloration from vitiligo.

Dr. Amit Pandya, Professor of Dermatology at UT Southwestern, refined and enhanced this technique, which uses a much less painful process quite compared to cutting in to the skin to obtain the cells required for the transplant. The cells are harvested from a painless blister raised on the skin, after that transferred to the area of involvement to replace the missing pigment cells and restore the individual’s natural skin color. UT Southwestern is the only Focus in the United States to use this technique and one of only two to perform this sort of cell transplant surgery, called non-cultured epidermal suspension (NCES) grafting, cellular grafting or melanocyte keratinocyte transplant procedure (MKTP).

“This provides brand-new chance for patients along with vitiligo,” said Dr. Pandya, that holds the Dr. J.B. Shelmire Professorship in Dermatology. “The unique aspect of our procedure, which no one else worldwide is doing, is the formation of blisters as the source of donor cells combined along with laser surgery to prepare the grafted areas. The older means of cutting the skin leaves a scar.”

Dr. Pandya, the only full-time pigmentary disorders specialist in Texas, has actually spent a lot more compared to a decade treating vitiligo patients in the Pigmentation Disorders Clinic at UT Southwestern.

Vitiligo affects regarding 2 million individuals in the United States. Vitiligo occurs as soon as the physique is triggered to consider melanocytes, cells which provide color to the skin, as foreign or abnormal. along with vitiligo, the body’s own immune system starts attacking those cells, which is why it’s considered an autoimmune disease. Traditional treatments include phototherapy, requiring different types of machines to shine ultraviolet light on the whole body, localized areas, or the hands and feet. UT Southwestern likewise uses an excimer laser to treat smaller sized lesions.

For the transplant procedure, Dr. Pandya uses a syringe and a heat lamp to produce a small blister graft on the thigh. Thousands of cells are removed from the blister roof and those cells are after that applied to the affected area.

“It doesn’t even hurt. It feels love something is sucking on your skin. after that using heat lamps we’re able to form blisters regarding the size of a dime,” explained Dr. Pandya, that traveled to China, India, and Detroit to be trained in non-cultured epidermal suspension grafting. Numerous patients seeking these treatments previously had traveled across continents to Europe and Asia, where the treatments were initially developed.

Blistering leaves pigmentation, which slowly fades over time. Dr. Pandya can easily use a blister only 0.7 centimeters to cover a spot 10 times as large. After the cells are extracted from the blister roof they are put in to a solution in a syringe that is dripped on the affected area. Thousands of melanocytes are transplanted in to the areas of vitiligo along with each procedure. Exactly how Numerous procedures are needed depends on the size of the area affected.

Good candidates for the NCES procedure have actually steady vitiligo, in which not a lot more compared to 10 percent worsening has actually been seen in the last year and patients along with segmental vitiligo, a type that appears on only one adverse of the face or body.

“The very best candidates have actually improved along with previous treatments however have actually reached a standstill in which they are neither boosting nor worsening,” said Dr. Pandya.

The donor blisters can easily come from the abdomen, thighs, or buttocks. Areas that respond well include the cheeks, forehead, neck, back, chest, abdomen, arms, and legs. The nose, skin about the mouth, lips, elbows, wrists, fingers, knees, ankles, and toes have actually a lower response. While most patients see at least 50 percent of their normal color returning to the treated area, victory is not guaranteed and sometimes no pigmentation is seen after the procedure. The color of the brand-new pigmentation could be lighter, darker, or blotchier compared to the normal surrounding skin, he said. Repigmentation can easily be sped up by using phototherapy once bandages have actually been removed in one week.

Dr. Pandya served as co-editor of the recently-published Dermatology Atlas for Skin of Color, which includes 50 chapters, a lot more compared to 400 images, and concise discussions to address the presentation of common skin disorders in pigmented patients. Dr. Pandya likewise serves as medical director for the DFW Vitiligo Support Group, whose mission is to educate those along with vitiligo regarding the diagnosis and treatment of vitiligo, to offer support for those affected by vitiligo, and to raise awareness of this disorder in the general public.

In addition to ongoing research to discover an eventual cure for vitiligo, Dr. Pandya is compiling one of only 5 vitiligo registries worldwide that collects data on patients and the disease. The Dallas Vitiligo Registry (DVR) is a national registry for vitiligo patients. Its target is to enroll a large number (hundreds) of patients in order to much better understand the sets off of vitiligo, Exactly how it evolves over time, and Exactly how to treat vitiligo optimally. Among the targets is to follow patients receiving various therapies to figure out which job finest and for which types of vitiligo. Patients likewise are evaluated for disease associations such as thyroid disease, which occur in higher frequency in patients along with vitiligo. The creation of a unified database that measures and tracks these factors over a long period of time will certainly offer higher assistance in to the disease process and get there the boundaries of current research in the field. Additionally, measuring response or progression of disease along with different treatments over longer periods of time will certainly recommendations physicians to improve their treatment protocols for affected patients.

Syneron Medical to Report Second Quarter 2015 Financial Results on August 4, 2015






<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://photos.prnewswire.com/prnvar/20120528/535447?max=400 –>















IRVINE, Calif., July 17, 2015 /PRNewswire/ — Syneron Medical Ltd. (NASDAQ: ELOS), a top global aesthetic device company, today announced that it will certainly launch second quarter 2015 financial outcomes prior to the market opens on Tuesday, August 4, 2015. The earnings launch will certainly be readily available on Syneron’s website at www.investors.syneron.com.

Syneron management will certainly host a conference call and a live webcast at 8:30 a.m. (ET) on the very same day. A question & answer session will certainly follow management’s discussion of events in the second quarter 2015.

Investors and analysts might participate in the conference call utilizing the complying with dial-in numbers:

US (toll free):    (877) 280-2342
International:     (646) 254 3366 

The conference passcode for the two is 2999072.

Investors and others interested parties can easily additionally access a live webcast of the conference call through the Investor Relations page on Syneron’s website at www.investors.syneron.com. Please log-in at the very least 10 moments prior to the conference call in order to download the applicable audio software. complying with the conclusion of the call, a replay of the webcast will certainly be readily available within 24 hrs on the Company’s website.

About Syneron Candela:
Syneron Candela is a top global aesthetic device business along with a comprehensive product portfolio and a global distribution footprint.  The Company’s technology permits physicians to give advanced solutions for a broad range of medical-aesthetic applications including non-invasive fat destruction, physique contouring, hair removal, wrinkle reduction, tattoo removal, boosting the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The business sells its products under 3 distinct brands, Syneron, Candela and CoolTouch, and has actually a wide portfolio of trusted, top products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay and elos Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela additionally has actually R&D and manufacturing operations in the U.S.  The business markets, solutions and maintains its products in 86 countries.  It has actually offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia,China, Japan, and Hong Kong and distributors worldwide.

For added information, please visit http://www.syneron-candela.com.

Logo – http://photos.prnewswire.com/prnh/20120528/535447

SOURCE Syneron Medical Ltd.

RELATED LINKS
http://www.syneron-candela.com

Removing more tissue during breast cancer surgery reduces by half the need for second procedure

Removing a lot more tissue throughout a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Focus study. The findings were published online Could 30 in the Brand-new England Diary of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.

Nearly 300,000 women in the United States are diagnosed along with breast cancer each year; a lot more compared to half undergo breast-conserving surgery along with a partial mastectomy to remove the disease. However, in between 20% and 40% of patients that undergo this procedure have actually “beneficial margins,” or cancer cells located at the edge of just what is removed. The presence of beneficial margins regularly leads to a second surgery to make sure that no cancer remains. The Yale study explored Exactly how removing a lot more tissue all of the method about the tumor site throughout the very first surgery — known as cavity shave margins (CSM) — could decrease the demand for a second surgery.

In this study of 235 patients along with breast cancer ranging from phase 0 to phase III, surgeons performed a partial mastectomy as they normally would. Patients were after that randomized in the operating room to either have actually extra CSM removed or not.

“Despite their finest efforts, surgeons could not predict where the cancer was close to the edge,” said the study’s lead author, Dr. Anees Chagpar, associate professor of surgery (oncology) at Yale School of Medicine and director of The Breast Focus at Smilow Cancer Hospital at Yale-Brand-new Haven. “Taking cavity shave margins reduce the beneficial margin price in half, free of compromising cosmetic outcome or increasing complication rates.” Patients in the study will certainly be followed for 5 years to evaluate the impact of the technique on recurrence rates.

“This randomized controlled trial has actually the potential to have actually a substantial impact for breast cancer patients,” Chagpar said. “No one likes going spine to the operating room, especially not the patients that face the emotional burden of an additional surgery.”

Patients on the study were enrolled at Smilow Cancer Hospital at Yale-Brand-new Haven.

Additional authors on the study consist of Brigid K. Killelea, M.D.; Meghan Butler; Karen Stavris; Fangyong Li; Xiaopan Yao; Veerle Bossuyt, M.D.; Malini Harigopal, M.D.; Donald R. Lannin, M.D.; Lajos Pusztai, M.D.; Nina R. Horowitz, M.D., all of from Yale University; and Theodore N. Tsangaris, M.D., of Thomas Jefferson University Hospital.

Story Source:

The above guide is reprinted from materials offered by Yale Cancer Center. The original item was written by Vicky Agnew. Note: components might be edited for content and length.